

<Original Article>

Mild acid hydrolysis of sphingolipids yields lysosphingolipids: a matrix-assisted laser desorption and ionization time-of-flight mass spectrometry study

Hiroya Hidaka^{*1)}, Masaki Takiwaki²⁾, Mine Yamashita²⁾, Shinya Otsuki¹⁾, Kenji Kawasaki³⁾, Mitsutoshi Sugano³⁾ and Takayuki Honda⁴⁾

Summary The mechanisms underlying the generation of lysosphingolipids remain unclear. The present study investigated whether sphingolipids can be de-*N*-acylated under relatively mild acidic conditions to produce lysosphingolipids. Sphingolipids (ceramide, sphingomyelin, cerebroside, lactosylceramide, trihexosylceramide, globoside and Forssman glycolipid) were dissolved in chloroform/methanol (2:1 v/v) and then treated with 0.5N HCl at room temperature. The hydrolysis products were analyzed using thin layer chromatography and matrix-assisted laser desorption and ionization time-of-flight (MALDI-TOF) mass spectrometry. We found that for all sphingolipid species tested, the relatively mild acid treatment resulted in the production of a de-*N*-acylated sphingolipid. A time-course study showed that approximately 15% of the sphingomyelin sample was hydrolyzed in the first 24 h of treatment, and that hydrolysis continued at a slower rate for 3 weeks thereafter. It appeared that sphingolipid deacylation was induced by cyclic elimination of a fatty acid due to *N*-acyl to *O*-acyl conversion. The present findings indicate that lysosphingolipids can be generated from sphingolipids under relatively mild acidic conditions.

Key words: Sphingomyelin, Lysosphingomyelin, Ceramide, Glycosphingolipid, Mass analysis

1. Introduction

Sphingolipids are important constituents of cell membranes, plasma lipoproteins, rafts and caveoli¹⁻⁶⁾.

Sphingolipids are synthesized in cytoplasm and are hydrolyzed in lysosomes⁷⁾. Sphingolipid metabolites have been implicated as modulators of membrane signal transduction systems^{8, 9)}, and accumulate in

¹⁾Department of Biomedical Laboratory Sciences, School of Health Sciences, Shinshu University School of Medicine.

3-1-1 Asahi, Matsumoto, Nagano 390-8621, Japan

²⁾Clinical Laboratory Center, Toyama University Hospital. Toyama 930-0194, Japan

³⁾Department of Laboratory Medicine, Shinshu University Hospital.

3-1-1 Asahi, Matsumoto, Nagano 390-8621, Japan

⁴⁾Department of Laboratory Medicine, School of

Medicine, Shinshu University School of Medicine. 3-1-1 Asahi, Matsumoto, Nagano 390-8621, Japan

*Correspondence: Hiroya Hidaka, Ph.D.

Department of Biomedical Laboratory Sciences, School of Health Sciences, Shinshu University School of Medicine.

3-1-1 Asahi, Matsumoto, Nagano 390-8621, Japan

Received for Publication April 11, 2012

Accepted for Publication April 12, 2012

lysosomal enzyme-deficient diseases such as sphingolipidosis¹⁰⁻¹². Recently, small amounts of lysosphingolipids have been detected in plasma lipoproteins^{13, 14}. However, the mechanism of generation of these lysosphingolipids and their role in plasma and cells remains unclear.

The sphingolipid amide linkage between the fatty acid and the sphingosine base is extremely stable, and as such, analysis of those long chain bases and the fatty acid composition requires strongly acidic or alkaline hydrolysis at high temperature. In general, sphingolipid hydrolysis for the preparation of lysosphingolipid is performed under strongly alkaline conditions for several hours at high temperature^{15, 16}. The alternate approach of acid hydrolysis is assumed to cause an *N* → *O* shift of the *N*-acyl chain and the formation of a cyclic intermediate such as an oxazolidine ring, after which various by-products of the long chain base are generated after deacylation. However, Van Veldhoven et al.¹⁷ recently reported that relatively mild acid treatment (0.5N HCl for 3 hours at room temperature) of the *N*-[¹⁴C] acetyl-sphingenine of ceramide resulted in the formation of three by-products, 1-*O*-acetyl-sphingenine, 3-*O*-acetyl-sphingenine and sphingenine, all of which were ninhydrin-positive.

In vivo, ceramide is hydrolyzed by ceramidase into fatty acids and long chain bases. However, there are no reports of enzyme hydrolysis of this sphingolipid into fatty acids and lysosphingolipid in humans. Very small amounts of lysosphingolipid are detected in humans¹⁸, and may be associated with a predisposition to genetic sphingolipidosis diseases. Lysosphingolipid generation from accumulated sphingolipid due to enzyme deficiency may be the result of *N*-acyl conversion into *O*-acyl, which is hydrolyzed by lipid esterase in lysosomes.

Abbreviations

Chloroform/methanol; C/M, matrix-assisted laser desorption and ionization time-of-flight; MALDI-TOF, 2,5-dihydroxybenzoic acid; 2,5-DHB, thin layer chromatography; TLC, cerebroside; CMH, lactosylceramide; CDH, trihexosyl ceramide; CTH, *m/z*: mass/charge, LCB: long chain base, FA: fatty acid

Matrix-assisted laser desorption and ionization time-of-flight (MALDI-TOF) mass spectrometry is useful for sphingolipid characterization^{19, 20}. In addition, the products of sphingosine bases following acid hydrolysis of sphingomyelin, cerebroside or psychosine have been measured using gas-liquid chromatography, thin layer chromatography (TLC), mass spectrometry and NMR-spectrometry²¹.

The present study investigated whether treatment of a variety of sphingolipids under relatively mild acidic conditions can result in the generation of lysosphingolipids due to de-*N*-acylation. MALDI-TOF mass spectrometry and TLC were used to analyze the hydrolysis.

2. Experimental

2.1. Chemicals

Methanol, chloroform, hydrochloric acid, aqueous ammonia and primuline reagent were obtained from Wako Chemical Co., (Osaka, Japan), and 2,5-dihydroxybenzoic acid (2,5-DHB) was purchased from SIGMA Chemical Co. (St. Louis, MO, USA). TLC plates with silica gel 60Å (100 x 100 mm, layer thickness; 250 μm), were obtained from Whatman (Maidstone, England).

2.2. Materials

The following purified sphingolipids were used: ceramide, sphingomyelin, cerebroside (CMH), lactosylceramide (CDH), trihexosyl ceramide (CTH), globoside and Forssman glycolipid²¹. Purified sphingenine, various lysosphingolipids, psychosin and sphingosylphosphorylcholine were used as reference standards.

2.3. Treatment with aqueous methanolic HCl

Purified sphingolipid (approximately 1 mg) was dissolved in 100 μl chloroform/ methanol (C/M, 2:1 v/v) solution containing 0.5N HCl. Following the reaction, the mixture was then dried under N₂ gas. Samples were re-dissolved in 2,5-DHB solution (10 mg/ml in C/M, 1:1 v/v) as a matrix, and analyzed using MALDI-TOF mass spectrometry.

2.4. Mass spectrometry

Mass spectrometer measurements were performed as previously described using a MALDI-TOF mass spectrometer (Voyager Elite XL, PerSeptive Biosystems, Framingham, MA)¹⁹. Extracted lipids were mixed with an equal quantity of 2,5-DHB, and 1 μ l of that mixture was applied to the spectrometer metal sample plate. The sample was allowed to dry, after which routine MALDI-TOF mass spectrometry analysis in positive ion mode was performed.

2.5. Thin layer chromatography

Samples (1 μ l of 1 mg/ml in C/M, 2:1 v/v) were applied to TLC silica gel plates and the plates were placed in a chamber with a solvent mixture of chloroform, methanol and aqueous ammonia (65: 35: 8, v/v/v). Lipids were visualized by spraying the plate with a solution of primuline reagent and then exposing the plate to UV light (366 nm).

3. Results

3.1. Degradation of sphingomyelin

Sphingomyelin was treated with 0.02, 0.1 or




Fig. 1 The generation of lysosphingomyelin following relatively mild acid hydrolysis of sphingomyelin. Untreated sphingomyelin or sphingomyelin treated for 3 weeks with various concentrations of HCl was subjected to TLC analysis as described in the Methods (developing solvent: chloroform, methanol and aqueous ammonia at 65:35:8 v/v/v ratio). Lane 1; untreated sphingomyelin, Lanes 2-5; sphingomyelin treated with 0.02, 0.1, 0.2 and 0.5N HCl, respectively.

0.5N HCl for 3 weeks at room temperature, and then analyzed using TLC. Untreated sphingomyelin (1 mg/ml in C/M, 2:1 v/v) appeared as two adjacent spots following TLC (Fig. 1). Treatment with 0.2 and 0.5N HCl resulted in the generation of lysosphingomyelin, whereas treatment with 0.02 or 0.1N HCl did not.

MALDI-TOF mass spectrometry analysis of untreated sphingomyelin revealed a number of ion peaks (Fig. 2-A). The peaks at m/z 669.8, 703.6, 725.6, 781.8, 815.7 and 837.7 represented various sphingomyelin molecular species containing different fatty acids. An ion peak at m/z 413.4 represented the sodium ion of 2,5-DHB ($[M+Na]^+$). Treatment of sphingomyelin with 0.5N HCl for 3 weeks at room temperature resulted in a significant reduction in the intensity of the peaks between m/z 669.8 and 837.7, and the appearance of new peaks at m/z 465.6 and 487.6 (Fig. 2-B). The latter peaks were identified as protonated and sodium-positive sphingosylphosphorylcholins ($[M+H]^+$ and $[M+Na]^+$), respectively (Table 1).

A time-course study was performed to examine




Fig. 2 The effect of mild acid hydrolysis on sphingomyelin MALDI-TOF mass spectra. Sphingomyelin was treated without (A) or with (B) 0.5N HCl for 3 weeks at room temperature, and then analyzed using positive ion mode MALDI-TOF mass spectrometry.

Table 1 Identification of MALDI-TOF mass spectrometry molecular ion peaks formed following treatment of sphingomyelins with 0.5N HCl at room temperature.
m/z: mass/charge, LCB: long chain base = sphingosine bases, FA: fatty acid, M: identified compound (sphingolipids).

m/z mol.ion	LCB	FA	M	m/z mol.ion	LCB	FA	M
Sphingomyelin and lyso-sphingomyelin				Lactosylceramide (CDH) and lyso-CDH			
466[M+H] ⁺	d18:1	-	Lyso-SM	624[M+H] ⁺	d18:1	-	Lyso-CDH
488[M+Na] ⁺	d18:1	-	Lyso-SM	646[M+Na] ⁺	d18:1	-	Lyso-CDH
670[M+Na] ⁺	d18:1	C12	SM	885[M+Na] ⁺	d18:1	C16	CDH
704[M+H] ⁺	d18:1	C16	SM	901[M+Na] ⁺	d18:1	C16h	CDH
726[M+Na] ⁺	d18:1	C16	SM	969[M+Na] ⁺	d18:1	C22	CDH
782[M+Na] ⁺	d18:1	C20	SM	997[M+Na] ⁺	d18:1	C24	CDH
816[M+H] ⁺	d18:1	C24	SM	1011[M+Na] ⁺	d18:1	C25	CDH
838[M+Na] ⁺	d18:1	C24	SM	Trihexosyl ceramide (CTH) and lyso-CTH			
Ceramide (N-acyl sphingosine) and sphingosine				787[M+H] ⁺	d18:1	-	Lyso-CTH
264[M-2H ₂ O+H] ⁺	d18:1	-	Sphingosine	809[M+Na] ⁺	d18:1	-	Lyso-CTH
282[M-H ₂ O+H] ⁺	d18:1	-	Sphingosine	1046[M+Na] ⁺	d18:1	C16	CTH
300[M+H] ⁺	d18:1	-	Sphingosine	1131[M+Na] ⁺	d18:1	C22	CTH
509[M-OH] ⁺	d18:1	C14h	Ceramide	1159[M+Na] ⁺	d18:1	C24	CTH
521[M-OH] ⁺	d18:1	C16	Ceramide	1175[M+Na] ⁺	d18:1	C24h	CTH
537[M-OH] ⁺	d18:1	C16h	Ceramide	Globoside and lyso-Globoside			
561[M+Na] ⁺	d18:1	C16	Ceramide	990[M+H] ⁺	d18:1	-	Lyso-Globoside
565[M-OH] ⁺	d18:1	C18h	Ceramide	1012[M+Na] ⁺	d18:1	-	Lyso-Globoside
593[M-OH] ⁺	d18:1	C20h	Ceramide	1334[M+Na] ⁺	d18:1	C22	Globoside
621[M-OH] ⁺	d18:1	C22h	Ceramide	1362[M+Na] ⁺	d18:1	C24	Globoside
649[M-OH] ⁺	d18:1	C24h	Ceramide	1378[M+Na] ⁺	d18:1	C24h	Globoside
Cerebrosides (CMH) and psychosines(Lyso-CMH)				Forssman and lyso-Forssman			
463[M+H] ⁺	d18:1	-	Lyso-CMH	1215[M+Na] ⁺	d18:1	-	Lyso-Forssman
485[M+Na] ⁺	d18:1	-	Lyso-CMH	1469[M+Na] ⁺	d18:1	C16h	Forssman
739[M+Na] ⁺	d18:1	C16h	CMH	1483[M+Na] ⁺	d18:1	C17h	Forssman
751[M+Na] ⁺	d18:1	C18	CMH	1537[M+Na] ⁺	d18:1	C22	Forssman
767[M+Na] ⁺	d18:1	C18h	CMH	1565[M+Na] ⁺	d18:1	C24	Forssman
793[M+Na] ⁺	d18:1	C20:1h	CMH	1579[M+Na] ⁺	d18:1	C25	Forssman
807[M+Na] ⁺	d18:1	C22	CMH				
833[M+Na] ⁺	d18:1	C24:1	CMH				
835[M+Na] ⁺	d18:1	C24	CMH				
849[M+Na] ⁺	d18:1	C24:1h	CMH				
851[M+Na] ⁺	d18:1	C24h	CMH				
863[M+Na] ⁺	d18:1	C26	CMH				




Fig. 3 Time course of sphingomyelin hydrolysis. Pure sphingomyelin (1 mg/ml in C/M, 2:1 v/v) was treated with 0.5N HCl at room temperature. Samples were taken at the times indicated and analyzed in positive ion mode using MALDI-TOF MS. ●: Sphingomyelin (total height of peaks at m/z 703 and 725), △: lysosphingomyelin (total height of peaks at m/z 466 and 488).

the rate of lysosphingomyelin production during the 3-week treatment. We found that approximately 15% of the sphingomyelin sample was hydrolyzed in the first 24 h, after which degradation occurred at a slower rate over the 3-week period (Fig. 3).




Fig. 4 Mild acidic hydrolysis of ceramide. Ceramide (Cer) was treated without (A) or with (B) 0.5N HCl at room temperature for 1 week, and the products analyzed in positive ion mode using MALDI-TOF mass spectrometry.

3.2. Degradation of ceramide

We examined the effect of mild acid hydrolysis on




Fig. 5 Mild acidic hydrolysis of glycosphingolipids. Cerebroside (CMH; Gal-Cer) (panel A), lactosylceramide (CDH; Gal-Glu-Cer) (panel B) or trihexosyl ceramide (CTH; Gal-Gal-Glu-Cer) (panel C) was treated without (a) or with (b) 0.5N HCl at room temperature for one week, and the products analyzed in positive ion mode using MALDI-TOF mass spectrometry.

ceramides. MALDI-TOF mass spectrometry analysis of untreated ceramides with various fatty acids revealed ion peaks at m/z 508.7, 520.7, 536.8, 560.7, 564.8, 592.8, 620.8 and 648.9 (Fig. 4-A). The ion peak at m/z 177.1 represented the sodium ion of 2,5-DHB ($[M+Na]^+$). Following treatment with 0.5N HCl for one week at room temperature, additional ion peaks were detected at m/z 300.4, 282.4 and 264.4 (Fig. 4-B). Those peaks corresponded to protonated sphingosine ($[M+H]^+$), dehydroxy sphingosine ($[M-OH]^+$), and two protonated molecules of dehydrated sphingosine ($[M-2H_2O+H]^+$) (Table 1). In addition, there was a decrease in the intensity of peaks in the

region from m/z 508.8 to 648.9 (i.e., ceramide).

3.3. Degradation of glycosphingolipids

The effect of a 1-week treatment with 0.5N HCl at room temperature on three glycosphingolipids was investigated. MALDI-TOF mass spectrometry analysis of untreated cerebroside (CMH) revealed mass ion peaks at m/z 738.6, 750.7, 766.7, 792.8, 806.7, 832.8, 834.8, 848.8, 850.8 and 862.8 (Fig. 5-A-a). After treatment, two new ion peaks were detected at m/z 462.5 and 484.5 (Fig. 5-A-b), which were identified as individual molecular species of protonated and sodium-positive lysocerebroside (Table 1).




Fig. 6 Mild acidic hydrolysis of globosides with *N*-acetyl glucosamine. Globoside (GalNAc-Gal-Gal-Glu-Cer) (panel A) or Forssman glycolipid (GalNAc-GalNAc-Gal-Gal-Glu-Cer) (panel B) was treated without (a) or with (b) 0.5N HCl at room temperature for one month, and the products analyzed in positive ion mode using MALDI-TOF mass spectrometry.

Untreated lactosylceramide (CDH) showed MALDI-TOF mass ion peaks at m/z 884.9, 900.9, 969.0, 997.0 and 1011.0 (Fig. 5-B-a). After treatment, two new ion peaks were detected at m/z 624.4 and 646.4 (Fig. 5-B-b), and these were identified as protonated and sodium-positive lysolactosylceramide (Table 1).

Untreated globotriaosylceramide (CTH) produced MALDI-TOF mass ion peaks at m/z 1046.4, 1130.5, 1158.5 and 1174.5 (Fig. 5-C-a). Following treatment, two new ion peaks were detected at m/z 786.6 and 808.6 (Fig. 5-C-b), and these were identified as protonated and sodium-positive lysoglobotriaosylceramide (Table 1).

These results suggest that under mild acidic conditions, a gradual deacylation of neutral glycosphingolipids occurred irrespective of the number of hexose chains in the glycosidic linkage with the ceramide moiety.

3.4 Degradation of globosides with *N*-acetyl glucosamine

We investigated the effect of treatment with 0.5N HCl at room temperature on globoside, which contains

one *N*-acetyl glucosamine molecule, and on Forssman glycolipid, which contains two *N*-acetyl glucosamine molecules.

MALDI-TOF analysis of untreated globoside revealed ion peaks at m/z 1334.1, 1362.1 and 1378.1 (Fig. 6-A-a), and these were identified as individual molecular species of sodium-positive globoside (Table 1). After treatment with 0.5N HCl for approximately one month, those peaks could no longer be detected, and two new ion peaks were detected at m/z 989.6 and 1011.7 (Fig. 6-A-b), which were identified as protonated and sodium-positive lysogloboside (Table 1).

Untreated Forssman glycolipid MALDI-TOF mass ion peaks were detected at m/z 1468.8, 1482.8, 1536.9, 1564.9, and 1578.9 (Fig. 6-B-a). Treatment with 0.5N HCl for approximately one month resulted in the disappearance of those peaks, and the appearance of a new ion peak at m/z 1214.5 (Fig. 6-B-b), which was identified as an individual molecular species of the sodium-positive lyso-Forssman glycolipid (Table 1).

These data suggest that mild acidic treatment resulted in deacylation of *N*-acetylglucosamine-

containing glycosphingolipids without any hydrolysis of the glycosidic linkage.

4. Discussion

The present study using MALDI-TOF mass spectrometry found that deacylation of ceramide and sphingomyelin can occur under relatively mild acidic conditions. Indeed, this deacylation occurred in a range of glycosphingolipids with differing numbers of hexose chains. In addition, the deacylation was observed in glycosphingolipids with either one or two *N*-acetyl glucosamine molecules, and occurred without any hydrolysis of the glycosidic linkage. The findings indicate that relatively mild acidic treatment of sphingolipids can result in the generation of lysosphingolipids.

The current data indicate that sphingolipid deacylation under relatively mild acidic conditions may be induced by *N*-acyl conversion to *O*-acyl (*N* → *O*-acyl migration) through cyclic elimination of fatty acid. In general, *N* → *O*-acyl migration reactions occur under strongly acidic or high temperature conditions (e.g., *N*-acetyl-ephedrine, cyclosporine or cyclic and linear peptides)^{22, 23}. It was previously reported that the potential of the *N* → *O*-acyl migration reaction depends on a cyclic elimination of a fatty acid via a pyrolytic reaction and allylic rearrangement, as suggested by Weiss²⁴ in studies on the preparation of lysohematoside from hematoside of equine erythrocytes¹⁶. Recently, Van Overloop et al. reported that a very small amount of long chain bases was produced from *N*-[¹⁴C]acetyl-sphinganine hydrolyzed in 0.5N HCl for 3 hours at room temperature¹⁷. The by-products of *N*-[¹⁴C]acetyl-sphinganine deacetylation were identified as 1-*O*-acetyl-sphinganine, 3-*O*-acetyl-sphinganine and sphinganine based on their ninhydrin-positive reaction.

MALDI-TOF mass spectrometry in the reflector mode was found to be extremely effective in the analysis of the various lysosphingolipids together with their long chain base components. An advantage of this technique is that intramolecular decomposition is not required. The lysosphingolipid mass spectra provided the precise mass of the molecular-related

ions, and simultaneously indicated the constituents of the long chain base¹⁸.

To date, few studies have examined sphingolipid hydrolysis under relatively mild acidic conditions. The present study suggests that *N*-acyl to *O*-acyl conversion of sphingolipids is possible under such conditions. These findings that lysosphingolipids can be created under such conditions, and without a by-product, are likely to provide an important approach for future structural, functional and metabolic studies of lysosphingolipids.

5. Conclusion

In the present study, relatively mild acidic treatment of a range of sphingolipids resulted in the production of lysosphingolipids, and no by-products. This deacylation occurred for all sphingolipids species tested, and therefore appeared to be independent of the number or type sugar moiety.

Acknowledgments

We wish to thank Emeritus Professor Tamotsu Taketomi of Shinshu University for valuable advice and comments. Part of this study was supported by a Grant-in-Aid for Exploratory Research (20590563) from the Ministry of Education, Culture, Sports, Science, and Technology, Japan.

References

- 1) Menkes JH, Philippart M and Concone MC: Concentration and fatty acid composition of cerebro-sides and sulfatides in mature and immature human brain. *J Lipid Res*, 7: 479-486, 1966.
- 2) Karlsson KA, Samuelsson BE and Steen GO: Structure and function of sphingolipids. 1. Differences in sphingolipid long-chain base pattern between kidney cortex, medulla, and papillae. *Acta Chem Scand*, 22: 1361-1363, 1968.
- 3) Hara A and Taketomi T: Long chain base and fatty acid compositions of equine kidney sphingolipids. *J Biochem*, 78: 527-536, 1975.
- 4) Dawson G, Kruski AW and Scanu AM: Distribution of glycosphingolipids in the serum lipoproteins of normal human subjects and patients with hypo- and hyperlipidemias. *J Lipid Res*, 17: 125-131, 1976.
- 5) Pralle A, Keller P, Florin EL, Simons K and Hörber JK:

- Sphingolipid-cholesterol rafts diffuse as small entities in the plasma membrane of mammalian cells. *J Cell Biol*, 148: 997-1008, 2000.
- 6) Mendez AJ, Lin G, Wade DP, Lawn RM and Oram JF: Membrane lipid domains distinct from cholesterol/sphingomyelin-rich rafts are involved in the ABCA1-mediated lipid secretory pathway. *Biol Chem*, 276: 3158-3166, 2001.
 - 7) Koval M and Pagano RE: Intracellular transport and metabolism of sphingomyelin. *Biochim Biophys Acta*, 1082: 113-125, 1991.
 - 8) Simons K and Ikonen E: Functional rafts in cell membranes. *Nature*, 387: 569-572, 1997.
 - 9) Samsonov AV, Mihalyov I and Cohen FS: Characterization of cholesterol-sphingomyelin domains and their dynamics in bilayer membranes. *Biophys J*, 81: 1486-1500, 2001.
 - 10) Tallman JF, Johnson WG and Brady RO: The metabolism of Tay-Sachs ganglioside: catabolic studies with lysosomal enzymes from normal and Tay-Sachs brain tissue. *J Clin Invest*, 51: 2339-2345, 1972.
 - 11) Hozumi I, Nishizawa M, Ariga T and Miyatake T: Biochemical and clinical analysis of accumulated glycolipids in symptomatic heterozygotes of angiokeratoma corporis diffusum (Fabry's disease) in comparison with hemizygotes. *J Lipid Res*, 31: 335-340, 1990.
 - 12) Aerts JM, Hollak C, Boot R and Groener A: Biochemistry of glycosphingolipid storage disorders: implications for therapeutic intervention. *Philos Trans R Soc Lond B Biol Sci*, 358: 905-914, 2003.
 - 13) Theilmeier G, Schmidt C, Herrmann J, Keul P, Schäfers M, Herrgott I, Mersmann J, Larmann J, Hermann S, Stypmann J, Schober O, Hildebrand R, Schulz R, Heusch G, Haude M, von Wnuck Lipinski K, Herzog C, Schmitz M, Erbel R, Chun J and Levkau B: High-density lipoproteins and their constituent, sphingosine-1-phosphate, directly protect the heart against ischemia/reperfusion injury in vivo via the S1P3 lysophospholipid receptor. *Circulation*, 114: 1403-1409, 2006.
 - 14) Yatomi Y: Plasma sphingosine 1-phosphate metabolism and analysis. *Biochim Biophys Acta*, 1780: 606-611, 2008.
 - 15) Gaver RC and Sweeley CC: Method for methanolysis of sphingolipids and direct determination of long-chain bases by gas chromatography. *J Am Oil Chem Soc*, 42: 294-298, 1965.
 - 16) Taketomi T and Kawamura N: Preparation of lysohematoside from hematoside of equine erythrocyte and its chemical and hemolytic properties. *J Biochem*, 68: 475-485, 1970.
 - 17) Van Overloop H, Van der Hoeven G and Van Veldhoven P P: N-acyl migration in ceramides. *J Lipid Res*, 46: 812-816, 2005.
 - 18) Taketomi T, Hara A, Uemura K and Sugiyama E: Rapid method of preparation of lysoglycosphingolipids and their confirmation by delayed extraction matrix-assisted laser desorption ionization time-of-flight mass spectrometry. *J Biochem*, 120: 573-579, 1996.
 - 19) Hidaka H, Hanyu N, Sugano M, Kawasaki K, Yamauchi K and Katsuyama T: Analysis of human serum lipoprotein lipid composition using MALDI-TOF mass spectrometry. *Ann Clin Lab Sci*, 37: 213-221, 2007.
 - 20) Taketomi T and Kawamura N: Degradation of sphingosine bases during acid hydrolysis of sphingomyelin, cerebroside or psychosine. *J Biochem*, 72: 189-193, 1972.
 - 21) Taketomi T and Sugiyama E: Extraction and analysis of multiple sphingolipids from a single sample. *Methods Enzymol*, 312: 80-101, 2000.
 - 22) Oliyai R and Stella VJ: Kinetics and mechanism of isomerization of cyclosporin A. *Pharm Res*, 9: 617-622, 1992.
 - 23) Oliyai R, Siahaan TJ and Stella VJ: The importance of structural factors on the rate and the extent of N, O-acyl migration in cyclic and linear peptides. *Pharm Res*, 12: 323-328, 1995.
 - 24) Weiss B: Partial Identity of sphingosine methyl ethers. *Biochemistry*, 3: 1288-1293, 1964.